超早期静脉溶栓联合依达拉奉治疗对脑梗死患者炎症介质、氧化应激反应和神经功能的影响  

Effect of Ultra-early Intravenous Thrombolysis Combined with Edaravone on Inflammatory Factors, Oxidative Stress and Neurological Function in Patients with Acute Cerebral Infarction

作　　者：张鑫[1] 张福安 徐冰[1] ZHANG Xin;ZHANG Fu-An;XU Bing(Department of Neurology,Shenyang First People's Hospital,Shenyang 110041,China)

机构地区：[1]沈阳市第一人民医院神经内科

出　　处：《中国药物经济学》2019年第10期104-107,共4页China Journal of Pharmaceutical Economics

摘　　要：目的探讨超早期静脉溶栓联合依达拉奉治疗急性脑梗死患者的临床效果及作用机制。方法选取2017年8月至2019年1月沈阳市第一人民医院收治的88例急性脑梗死患者作为研究对象,依据治疗方案不同分为试验组与对照组,各44例。对照组单纯采用重组组织型纤溶酶原激活剂(rt-PA)方案治疗,试验组在对照组基础上采用依达拉奉注射液治疗,比较两组患者的治疗效果。结果两组患者治疗后超敏C反应蛋白(hs-CRP)、肿瘤坏死因子-α(TNF-α)及白细胞介素-1β(IL-1β)水平均明显降低,且试验组均低于对照组,差异有统计学意义(P<0.05)。治疗后,试验组患者丙二醛(MDA)水平明显低于对照组,谷胱甘肽过氧化物酶(GSH-Px)、超氧化物歧化酶(SOD)水平均明显高于对照组,差异有统计学意义(P<0.05)。治疗后,试验组患者美国国立卫生研究院卒中量表(NIHSS)评分明显低于对照组,差异有统计学意义(P<0.05)。试验组治疗有效率高于对照组,并发症发生率低于对照组,差异有统计学意义(P<0.05)。结论超早期脑梗死溶栓治疗联合依达拉奉能有效抑制患者炎症反应和氧化应激反应,减轻神经功能受损程度,提高临床治疗效果,降低并发症发生风险。Objective To explore the clinical effect and mechanism of ultra-early intravenous thrombolysis combined with edaravone in the treatment of acute cerebral infarction. Methods A total of 88 patients with acute cerebral infarction admitted to Shenyang First People’s Hospital from August 2017 to January 2019 were selected as the study subjects. They were divided into experimental group and control group according to different treatment schemes, with 44 cases in each group. The control group was treated with recombinant tissue plasminogen activator(rt-PA) alone. The experimental group was treated with edaravone injection on the basis of the control group. The therapeutic effects of the 2 groups were compared. Results The levels of Hypersensitive C-reactive protein(hs-CRP), Tumor necrosis factor-α(TNF-α) and Interleukin-1β(IL-1β) were significantly lowered in the 2 groups after treatment. The level in the experimental group was lower than that in the control group(P<0.05). After treatment, the MDA level of the experimental group was significantly lower than that of the control group, and the GSH-Px level and SOD level were significantly higher than the control group(P<0.05). After treatment, the NIHSS scores of the experimental group were significantly lower than those of the control group(P<0.05). The treatment efficiency of the experimental group was higher than that of the control group, and the complication rate was lower than that of the control group(P<0.05). Conclusion Ultra-early thrombolytic therapy combined with edaravone can effectively inhibit inflammation and oxidative stress, reduce neurological impairment, improve clinical efficacy and reduce the risk of complications.

关 键 词：急性脑梗死 超早期静脉溶栓 依达拉奉 氧化应激 神经功能 

分 类 号：R743.3[医药卫生—神经病学与精神病学] R971[医药卫生—临床医学]